Wall Street brokerages expect Immune Design Corp. (NASDAQ:IMDZ) to report ($0.39) earnings per share for the current quarter, Zacks reports. Two analysts have made estimates for Immune Design Corp.’s earnings, with the highest EPS estimate coming in at ($0.32) and the lowest estimate coming in at ($0.46). Immune Design Corp. posted earnings of ($0.57) per share in the same quarter last year, which suggests a positive year over year growth rate of 31.6%. The business is scheduled to issue its next earnings results on Tuesday, March 6th.

On average, analysts expect that Immune Design Corp. will report full year earnings of ($1.89) per share for the current year, with EPS estimates ranging from ($2.00) to ($1.76). For the next financial year, analysts forecast that the business will post earnings of ($1.40) per share, with EPS estimates ranging from ($1.58) to ($1.24). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that follow Immune Design Corp..

Immune Design Corp. (NASDAQ:IMDZ) last released its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.63) by $0.11. Immune Design Corp. had a negative return on equity of 68.69% and a negative net margin of 619.62%. The company had revenue of $0.52 million during the quarter, compared to the consensus estimate of $0.62 million.

IMDZ has been the subject of several recent research reports. Wells Fargo & Company downgraded Immune Design Corp. from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $29.00 to $10.00 in a research note on Tuesday, October 17th. ValuEngine downgraded shares of Immune Design Corp. from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 21st. Zacks Investment Research raised shares of Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research report on Tuesday, July 18th. Royal Bank Of Canada began coverage on shares of Immune Design Corp. in a research report on Thursday, September 14th. They set an “outperform” rating and a $20.00 target price for the company. Finally, BidaskClub downgraded shares of Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 5th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. Immune Design Corp. presently has a consensus rating of “Hold” and a consensus price target of $13.19.

ILLEGAL ACTIVITY WARNING: “Zacks: Brokerages Anticipate Immune Design Corp. (IMDZ) to Post -$0.39 EPS” was first published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The original version of this piece can be viewed at https://www.watchlistnews.com/zacks-brokerages-anticipate-immune-design-corp-imdz-to-post-0-39-eps/1703031.html.

Immune Design Corp. (NASDAQ:IMDZ) traded down $0.55 during trading on Friday, hitting $4.40. The stock had a trading volume of 724,500 shares, compared to its average volume of 287,012. Immune Design Corp. has a one year low of $3.78 and a one year high of $13.05.

In other news, Director Lewis W. Coleman bought 50,000 shares of the business’s stock in a transaction that occurred on Thursday, November 2nd. The shares were bought at an average cost of $4.50 per share, for a total transaction of $225,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Peter Svennilson bought 2,681,000 shares of the business’s stock in a transaction that occurred on Friday, October 27th. The stock was purchased at an average price of $4.10 per share, for a total transaction of $10,992,100.00. The disclosure for this purchase can be found here. Insiders have acquired a total of 5,300,000 shares of company stock worth $21,874,900 over the last 90 days. Company insiders own 20.70% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the stock. Bank of America Corp DE lifted its holdings in shares of Immune Design Corp. by 123.3% in the 1st quarter. Bank of America Corp DE now owns 15,246 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 8,418 shares in the last quarter. State of Wisconsin Investment Board purchased a new stake in Immune Design Corp. in the 2nd quarter valued at $117,000. Alliancebernstein L.P. purchased a new stake in Immune Design Corp. in the 2nd quarter valued at $118,000. Virtu KCG Holdings LLC purchased a new stake in Immune Design Corp. in the 2nd quarter valued at $153,000. Finally, Dimensional Fund Advisors LP raised its position in Immune Design Corp. by 9.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 18,896 shares of the biotechnology company’s stock valued at $184,000 after buying an additional 1,600 shares during the last quarter. Institutional investors own 51.74% of the company’s stock.

Immune Design Corp. Company Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Get a free copy of the Zacks research report on Immune Design Corp. (IMDZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Immune Design Corp. (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.